Mylotarg is a drug owned by Wyeth Pharmaceuticals Inc. It is protected by 6 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 30, 2015. Details of Mylotarg's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5773001 | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
Jun, 2015
(9 years ago) |
Expired
|
| US5767285 | Linkers useful for the synthesis of conjugates of methyltrithio antitumor agents |
Jun, 2015
(9 years ago) |
Expired
|
| US5739116 | Enediyne derivatives useful for the synthesis of conjugates of methyltrithio antitumor agents |
Apr, 2015
(9 years ago) |
Expired
|
| US5693762 | Humanized immunoglobulins |
Dec, 2014
(10 years ago) |
Expired
|
| US5606040 | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
Feb, 2014
(10 years ago) |
Expired
|
| US5585089 | Humanized immunoglobulins |
Dec, 2013
(11 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Mylotarg is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Mylotarg's family patents as well as insights into ongoing legal events on those patents.
Mylotarg's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Mylotarg's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 30, 2015 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Mylotarg Generics:
There are no approved generic versions for Mylotarg as of now.
About Mylotarg
Mylotarg is a drug owned by Wyeth Pharmaceuticals Inc. It is used for treating acute myeloid leukemia. Mylotarg uses Gemtuzumab Ozogamicin as an active ingredient. Mylotarg was launched by Wyeth Pharms Inc in 2000.
Approval Date:
Mylotarg was approved by FDA for market use on 17 May, 2000.
Active Ingredient:
Mylotarg uses Gemtuzumab Ozogamicin as the active ingredient. Check out other Drugs and Companies using Gemtuzumab Ozogamicin ingredient
Treatment:
Mylotarg is used for treating acute myeloid leukemia.
Dosage:
Mylotarg is available in injectable form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 5MG/VIAL | INJECTABLE | Discontinued | INJECTION |